§ 12-280-501. Written Guidelines and Procedures for Making Therapeutic Interchange and Therapeutically Equivalent Selections
If a nursing care facility or a long-term acute care hospital licensed under part 1 of article 3 of title 25 has a quality assessment and assurance committee that includes a pharmacist licensed under this article 280 and is established in accordance with 42 CFR 483.75, the quality assessment and assurance committee may establish a […]
§ 12-280-502. Therapeutic Interchange and Therapeutically Equivalent Selections for Nursing Care Facility or Long-Term Acute Care Hospital Patients – Rules
A pharmacy used by a nursing care facility or a long-term acute care hospital licensed under part 1 of article 3 of title 25 may make a therapeutic interchange or a therapeutically equivalent selection for a patient if, during the patient’s stay at the facility, the selection has been approved for the patient: In accordance […]
§ 12-280-601. Definitions
As used in this part 6: “Collaborative pharmacy practice agreement” means a written and signed agreement entered into voluntarily between one or more pharmacists licensed pursuant to this article 280 and one or more physicians or advanced practice registered nurses licensed in this state, which statement grants authority to the pharmacist or pharmacists to provide […]
§ 12-280-602. Collaborative Pharmacy Practice Agreements – Pharmacist Requirements
A pharmacist may enter into a collaborative pharmacy practice agreement with one or more physicians if: The pharmacist: Holds a current license to practice in Colorado; Is engaged in the practice of pharmacy; Has earned a doctorate of pharmacy degree or completed at least five years of experience as a licensed pharmacist; Carries adequate professional […]
§ 12-280-603. Rules
The board, in conjunction with the Colorado medical board created in section 12-240-105 and the state board of nursing created in section 12-255-105, shall promulgate rules to implement this part 6. The rules must include the health-care services and any statewide protocols that are authorized to be part of the collaborative pharmacy practice agreements. Source: […]
§ 12-280-405. Prescription Drug Monitoring Fund – Creation – Fee
The board may seek and accept money from any public or private entity for the purposes of implementing and maintaining the program. The board shall transmit any money it receives to the state treasurer, who shall credit the money to the prescription drug monitoring fund, which fund is hereby created. The money in the fund […]
§ 12-280-406. Violations – Penalties
A person who knowingly releases, obtains, or attempts to obtain information from the program in violation of this part 4 shall be punished by a civil fine of not less than one thousand dollars and not more than ten thousand dollars for each violation. Fines paid shall be deposited in the general fund in accordance […]
§ 12-280-407. Prescription Drug Outlets – Prescribers – Responsibilities – Liability
A prescription drug outlet shall submit information in the manner required by the board. A practitioner who has, in good faith, written a prescription for a controlled substance to a patient is not liable for information submitted to the program. A practitioner or prescription drug outlet who has, in good faith, submitted the required information […]
§ 12-280-408. Exemption – Waiver
A hospital licensed or certified pursuant to section 25-1.5-103, a prescription drug outlet located within the hospital that is dispensing a controlled substance for a chart order or dispensing less than or equal to a twenty-four-hour supply of a controlled substance, and an emergency medical service provider certified or licensed pursuant to section 25-3.5-203 are […]
§ 12-280-409. Examination and Analysis of Prescription Drug Monitoring Program – Recommendations to Executive Director
The executive director shall create a prescription drug monitoring program task force or consult with and request assistance from the Colorado team assembled by the governor’s office to develop a strategic plan to reduce prescription drug misuse, or its successor group, in order to: Examine issues, opportunities, and weaknesses of the program, including how personal […]